Skip to main content
INOVIO PHARMACEUTICALS, INC. logo

INOVIO PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · INO ISIN · US45773H4092 LEI · 529900B9W875XDZXTM97 US Manufacturing
Filings indexed 1,003 across all filing types
Latest filing 2025-07-01 Director's Dealing
Country US United States of America
Listing US INO

About INOVIO PHARMACEUTICALS, INC.

https://www.inovio.com/

INOVIO PHARMACEUTICALS, INC. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines. The company's core technology centers on designing proprietary DNA plasmids—small, circular DNA molecules that instruct the body's cells to produce specific, targeted proteins to combat disease. These DNA medicines are delivered into cells using the company's proprietary investigational CELLECTRA® smart devices. This platform is designed to enable in vivo protein production and achieve therapeutic effect without the use of chemical adjuvants, lipid nanoparticles, or viral vectors. The company's development pipeline targets HPV-related diseases, various cancers, and infectious diseases.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-07-01 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Inovio Pharmaceuticals, Inc. dated May 20, 2025. The content focuses on the submission of matters to a vote of security holders at the 2025 Annual Meeting of Stockholders, including detailed voting results for director elections, auditor ratification, executive compensation advisory vote, and plan amendment approval. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. The document is not an Annual Report, Proxy Statement, or Management Report but specifically reports voting outcomes. The length and detail confirm it is not a brief announcement or a certification. Therefore, the correct classification is DVA with high confidence.
2025-05-22 English
FORM 4
Director's Dealing
2025-05-21 English
FORM 4
Director's Dealing
2025-05-21 English
FORM 4
Director's Dealing
2025-05-21 English
FORM 4
Director's Dealing
2025-05-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.